ORLADEYO® (berotralstat)
Hereditary Angioedema (HAE) Prophylaxis (Adults & Pediatrics ≥12)
Key Facts
About BioCryst Pharmaceuticals
Founded in 1986, BioCryst Pharmaceuticals is a global, commercial-stage biotech company headquartered in Durham, North Carolina, focused on discovering and developing novel treatments for rare diseases. Its core expertise lies in structure-guided drug design, which it uses to create highly selective oral and injectable therapies. The company has successfully commercialized ORLADEYO for HAE and is advancing a pipeline of investigational candidates, including navenibart for HAE and BCX17725 for Netherton syndrome, while also marketing RAPIVAB for influenza.
View full company profileAbout BioCryst Pharmaceuticals
Founded in 1986, BioCryst Pharmaceuticals is a global, commercial-stage biotech company headquartered in Durham, North Carolina, focused on discovering and developing novel treatments for rare diseases. Its core expertise lies in structure-guided drug design, which it uses to create highly selective oral and injectable therapies. The company has successfully commercialized ORLADEYO for HAE and is advancing a pipeline of investigational candidates, including navenibart for HAE and BCX17725 for Netherton syndrome, while also marketing RAPIVAB for influenza.
View full company profile